What does VistaGen Therapeutics, Inc. do?

Jun 22 2025 06:48 PM IST
share
Share Via
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. It has a market cap of $69.01 million and reported no net sales with a net loss of $14 million as of December 2024.
Overview:
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS) within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.

Financial Snapshot:
Most recent Net Sales: 0 Million (Quarterly Results - Dec 2024)
Most recent Net Profit: -14 Million (Quarterly Results - Dec 2024)
Market cap: USD 69.01 Million (Micro Cap)

Key Metrics:
P/E: NA (Loss Making)
Industry P/E: NA
Dividend Yield: 0.00%
Debt Equity: -1.08
Return on Equity: -58.31%
Price to Book: 0.85

Contact Details:
Address: 343 Allerton Ave, SOUTH SAN FRANCISCO CA: 94080-4816
Tel: ['1 650 5773600', '1 212 8961254']
Website: https://www.vistagen.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Is VistaGen Therapeutics, Inc. overvalued or undervalued?
Sep 20 2025 06:26 PM IST
share
Share Via
Is VistaGen Therapeutics, Inc. overvalued or undervalued?
Jun 25 2025 09:04 AM IST
share
Share Via
How big is VistaGen Therapeutics, Inc.?
Jun 22 2025 06:05 PM IST
share
Share Via